附註:Includes bibliographical references (pages 320-345) and index.
Preface -- 1 The background -- Introduction -- The Golden Age -- The chlorpromazine story -- In the wake of chlorpromazine -- Practice, theory and names -- 'Typicality' versus 'atypicality' -- 2 Some preliminaries -- The need for vigilance -- The classification of drug-related movement disorders -- The villains of the piece -- A small caveat -- 3 Acute dystonias -- Introduction -- The concept of dystonia -- Clinical features -- Diagnosis -- Epidemiology -- Predisposing factors -- Onset, course and outcome -- Treatment -- Pathophysiology.
Addendum: acute dystonias and oculogyric crises -- 4 Parkinsonism -- Introduction -- Terminology -- Clinical features -- Diagnosis -- Epidemiology -- Predisposing factors -- Onset, course and outcome -- Treatment -- Pathophysiology -- 5 Akathisia -- Introduction -- Terminology and concepts -- Clinical features -- Modifying factors -- Diagnosis -- Epidemiology -- Predisposing factors -- Onset, course and outcome -- Treatment -- Pathophysiology -- 6 Tardive dyskinesia -- Introduction -- The concept of tardive dyskinesia -- Clinical features -- Operationalised criteria for tardive dyskinesia.
Modifying factors -- Diagnosis -- Epidemiology -- Predisposing factors -- Onset, course and outcome -- Treatment -- Pathophysiology -- Clinical subtypes -- 7 Tardive and chronic dystonia -- Introduction -- Definition and classification of chronic dystonia -- Clinical features -- Characteristics of dystonia -- Diagnosis -- Epidemiology -- Predisposing factors -- Onset, course and outcome -- Treatment -- 8 Involuntary movements and schizophrenia: a limitation to the concept of tardive dyskinesia? -- Introduction -- The descriptive evidence -- The Shenley Study.
The limitations of the concept of tardive dyskinesia -- 9 Special populations -- Children and adolescents -- Learning disability -- The elderly -- Acquired immune deficiency syndrome -- 10 The clinical examination -- Introduction -- Preliminaries -- The standardised examination -- 11 An overview of some standardised recording instruments -- Introduction -- The origins of rating scales for movement disorders -- Principles involved in rating scales -- Standardised rating scales for Parkinson's disease -- Standardised rating scales for drug-related parkinsonism.
Standardised rating scales for tardive dyskinesia -- Standardised rating scales for akathisia -- Standardised rating scales for dystonia -- Combined rating scales -- Learning disability -- Some general issues -- The choice of scale -- 12 Some medicolegal and quality-of-care issues -- Introduction -- 'Informing' consent -- The medicolegal dimension -- New drugs for old? -- Some practical suggestions -- References -- Index.
摘要:Antipsychotic drugs have revolutionised the management of major psychiatric disorders and the outcomes of those who suffer from them. They are, however, possessed of a range of adverse effects, amongst the most frequent and distressing of which are those resulting in disturbance of voluntary motor function. Extrapyramidal side effects - or E.P.S. - are still poorly recognised and not infrequently misattributed. Despite a vast research literature, there have been few attempts to bring together both the descriptive clinical elements of these disorders and major research conclusions pertinent to routine practice. This very readable and well illustrated 1999 book seeks to rectify this in the hope of increasing clinicians' awareness of the issues and acknowledgement of their impact. This is a task made more rather than less urgent with the emergence of drugs of lower liability but which may promote subtler abnormality than standard compounds.
